Skip to main content

Table 1 Study inclusion and exclusion criteria

From: “Chronic fatigue, quality of life and long-term side-effects of chemotherapy in patients treated for non-epithelial ovarian cancer: national case-control protocol study of the GINECO-Vivrovaire rare tumors INCa French network for rare malignant ovarian tumors”

 

Group of interest

Patient control group

Healthy control group

Step 1

134 ovarian Germ Cell Tumor or Sex Cord Stromal tumor survivors

67 ovarian Germ Cell Tumor or Sex Cord Stromal tumor survivors

67 healthy women

Step 2

90 ovarian Germ Cell Tumor or Sex Cord Stromal tumors survivors

45 ovarian Germ Cell Tumor or Sex Cord Stromal tumor survivors

Not applicablea

Inclusion criteria

≥ 18 years old

≥ 18 years old

≥ 18 years old

 

Age-matched to group of interest (± 2 years)

Age-matched to group of interest (± 2 years)

Patient treated with surgery and BEP chemotherapy (≥ 1 cycle)

Patient treated with surgery alone (with or without fertility sparing).

 

Patient in remission ≥2 years after initial treatment

Patient in remission ≥2 years after initial treatment

 

Recurrence authorized if remission more than 2 years after end of initial treatment

Recurrence authorized if remission more than 2 years after the end of initial treatment

 

Patient with no other cancers (except basal cell skin carcinoma, breast cancer and cervical cancer)

Patient with no other cancers (except basal cell skin carcinoma, breast cancer and cervical cancer)

Women without cancer or serious chronic diseases

Patient having signed consent to participate

Patient having signed consent to participate

Healthy women accepted to complete online self-reported questionnaires

Exclusion criteria

Pregnant or breastfeeding woman

Psychiatric disorders

Major subject to legal protection or unable to express consent

  1. BEP Bleomycin, Etoposide and Cisplatinum
  2. a: Healthy control group participated only in step 1 of study (self-reported questionnaire)